| Apr 18 |
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
|
| Apr 1 |
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant An...
|
| Mar 26 |
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
|
| Mar 19 |
Actinium spikes as H.C. Wainwright highlights buyout prospects after Fusion deal
|
| Mar 15 |
High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment
|
| Mar 11 |
Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
|
| Feb 28 |
Actinium Pharmaceuticals: Closer To Realizing Its Potential (Rating Upgrade)
|
| Feb 27 |
Actinium shares surge on promising data for AML radiotherapy candidate
|
| Feb 26 |
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CI...
|
| Feb 23 |
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and ...
|
